Acrivon therapeutics presents data demonstrating capabilities of its ap3 platform and acr-368 oncosignature assay for patient responder identification at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics

Data presented on the application of acrivon predictive precision proteomics (ap3) for the successful development and extensive evaluation of the acr-368-tailored, proteomics-based oncosignature assay for the prediction of patients, as well as tumor types, most likely to respond to the chk1/2 inhibitor acr-368
ACRV Ratings Summary
ACRV Quant Ranking